An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer

Ming Chen,Jiangwen Zhang,Katia Sampieri,John G. Clohessy,Lourdes Mendez,Enrique Gonzalez-Billalabeitia,Xue-Song Liu,Yu-Ru Lee,Jacqueline Fung,Jesse M. Katon,Archita Venugopal Menon,Kaitlyn A. Webster,Christopher Ng,Maria Dilia Palumbieri,Moussa S. Diolombi,Susanne B. Breitkopf,Julie Teruya-Feldstein,Sabina Signoretti,Roderick T. Bronson,John M. Asara,Mireia Castillo-Martin,Carlos Cordon-Cardo,Pier Paolo Pandolfi
DOI: https://doi.org/10.1038/s41588-017-0027-2
IF: 30.8
2018-01-15
Nature Genetics
Abstract:Lipids, either endogenously synthesized or exogenous, have been linked to human cancer. Here we found that PML is frequently co-deleted with PTEN in metastatic human prostate cancer (CaP). We demonstrated that conditional inactivation of Pml in the mouse prostate morphs indolent Pten-null tumors into lethal metastatic disease. We identified MAPK reactivation, subsequent hyperactivation of an aberrant SREBP prometastatic lipogenic program, and a distinctive lipidomic profile as key characteristic features of metastatic Pml and Pten double-null CaP. Furthermore, targeting SREBP in vivo by fatostatin blocked both tumor growth and distant metastasis. Importantly, a high-fat diet (HFD) induced lipid accumulation in prostate tumors and was sufficient to drive metastasis in a nonmetastatic Pten-null mouse model of CaP, and an SREBP signature was highly enriched in metastatic human CaP. Thus, our findings uncover a prometastatic lipogenic program and lend direct genetic and experimental support to the notion that a Western HFD can promote metastasis.
genetics & heredity
What problem does this paper attempt to address?